NCT00295282 - A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Ulcerative Colitis

Interventions

DRUG

MDX-1100 (anti-CXCL10 human monoclonal antibody)

Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.

Trial Locations (5)

10029

Mount Sinai School of Medicine, New York

20815

Metropolitan Gastroenterology Group, PC, Chevy Chase

33773

DMI Health Care Group, Inc., Largo

90048

Cedars-Sinai Medical Center, Los Angeles

08903

University of Medicine and Dentistry of New Jersery (UMDNJ), New Brunswick